Enhancing Early Phase Cardiac Assessments: Join Our Free Webinar on EPQT and AI Innovations
The importance of cardiac assessments in early phase clinical trials cannot be overstated, particularly in light of the growing complexity and difficulty associated with needing precise safety data for novel therapeutics. To help bridge this gap, Xtalks is excited to announce a free webinar focused on enhancing these assessments through Early Precision QT (EPQT) methodologies and AI-powered data quality checks. This insightful session will be delivered by leading experts in cardiology and technology, aimed at drug developers, researchers, and stakeholders invested in early phase trials.
Event Details:
What You Will Learn:
In the realm of drug development, especially during Phase I trials, accurate and timely data on cardiac safety is crucial. Attendees will gain insights into:
Traditionally, the evaluation of QT intervals has occurred later during clinical development through Thorough QT (TQT) studies, often posing significant delays and resource allocation challenges. The proactive approach of performing QT assessments during early Phase I trials on healthy volunteers makes it possible to detect critical changes sooner. However, manual interpretations from investigators do not always yield the precision required to satisfy regulatory standards.
By integrating AI technology into early-phase QT assessments, drug developers can achieve a notable enhancement in safety data precision. The innovative combination of EPQT and AI strategies enables a comprehensive understanding of a drug's cardiac impact much earlier in its lifecycle. Such advancements in assessment not only enhance workflow efficiency but can also lead to substantial cost savings. By potentially supporting waivers for TQT studies, drug developers can circumvent extensive, multi-million dollar examinations down the line.
During the session, distinguished speakers, including Vic Patel, MD, PhD, Chief Medical Officer at Clario, and Dr. Borje Darpo, MD, PhD, Chief Scientific Officer at Clario, will delve into critical factors influencing decisions regarding QT waivers. They will highlight key metrics associated with the integration of AI in clinical assessments and demonstrate how this improved model can protect against possible toxicities, thereby fostering a more effective drug development pipeline.
In addition to academic insights, the webinar will afford participants an opportunity to engage in an interactive Q&A session, allowing them to seek clarifications and guidance on integrating these technologies into their own practice. The live demonstration of AI capabilities in analyzing ECGs promises to provide attendees with tangible takeaways that they can apply in their research environments.
Don’t miss this opportunity to enhance your understanding of cardiac assessments through innovative technologies. To register for the webinar, please visit the official Xtalks website. Join us on January 14, 2026, to discover how to leverage early-phase assessment tools effectively to secure data quality, streamline processes, and safeguard your future drug development projects.
For further inquiries about hosting a webinar or details about the session, feel free to contact Xtalks directly. We hope to see you at the webinar and look forward to equipping you with the knowledge to facilitate cutting-edge advancements in cardiac safety assessments.
Event Details:
- - Date: January 14, 2026
- - Time: 11 AM EST (5 PM CET)
- - Format: Live Webinar (Registration required)
What You Will Learn:
In the realm of drug development, especially during Phase I trials, accurate and timely data on cardiac safety is crucial. Attendees will gain insights into:
- - The advantages of harnessing AI for ECG analysis, providing automatic quality assessments that enhance the reliability of QT interval data.
- - How EPQT methodologies facilitate the collection of actionable safety information earlier in the development process, which may support regulatory waivers for standalone QT studies.
- - The pivotal role that prompt feedback on ECG quality plays in minimizing the risk of reporting inaccuracies and missing data, which are essential components for obtaining QT waivers from health authorities.
Traditionally, the evaluation of QT intervals has occurred later during clinical development through Thorough QT (TQT) studies, often posing significant delays and resource allocation challenges. The proactive approach of performing QT assessments during early Phase I trials on healthy volunteers makes it possible to detect critical changes sooner. However, manual interpretations from investigators do not always yield the precision required to satisfy regulatory standards.
By integrating AI technology into early-phase QT assessments, drug developers can achieve a notable enhancement in safety data precision. The innovative combination of EPQT and AI strategies enables a comprehensive understanding of a drug's cardiac impact much earlier in its lifecycle. Such advancements in assessment not only enhance workflow efficiency but can also lead to substantial cost savings. By potentially supporting waivers for TQT studies, drug developers can circumvent extensive, multi-million dollar examinations down the line.
During the session, distinguished speakers, including Vic Patel, MD, PhD, Chief Medical Officer at Clario, and Dr. Borje Darpo, MD, PhD, Chief Scientific Officer at Clario, will delve into critical factors influencing decisions regarding QT waivers. They will highlight key metrics associated with the integration of AI in clinical assessments and demonstrate how this improved model can protect against possible toxicities, thereby fostering a more effective drug development pipeline.
In addition to academic insights, the webinar will afford participants an opportunity to engage in an interactive Q&A session, allowing them to seek clarifications and guidance on integrating these technologies into their own practice. The live demonstration of AI capabilities in analyzing ECGs promises to provide attendees with tangible takeaways that they can apply in their research environments.
Don’t miss this opportunity to enhance your understanding of cardiac assessments through innovative technologies. To register for the webinar, please visit the official Xtalks website. Join us on January 14, 2026, to discover how to leverage early-phase assessment tools effectively to secure data quality, streamline processes, and safeguard your future drug development projects.
For further inquiries about hosting a webinar or details about the session, feel free to contact Xtalks directly. We hope to see you at the webinar and look forward to equipping you with the knowledge to facilitate cutting-edge advancements in cardiac safety assessments.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.